Physician profile
Hilary Lash
NPI 1801839394
$381.18
in general payments reported to CMS, 2019-2025
13 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.15 · 2023: $96.77 · 2024: $148 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $68.54 | 2024-2025 | Airsupra |
| Lilly USA, LLC | $50.34 | 2023-2024 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $48.99 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.57 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $33.82 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $24.15 | 2021 | |
| Exact Sciences Corporation | $19.87 | 2025 | The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $18.48 | 2024 | Tirosint, Licart |
| Ironshore Pharmaceuticals INC. | $17.43 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.99 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $14.85 | 2023 | Trelegy Ellipta, Shingrix |
| Agile Therapeutics, INC. | $13.44 | 2024 | Twirla |
| Kowa Pharmaceuticals America, INC. | $12.71 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hilary Lash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.